Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5058353> ?p ?o }
Showing triples 1 to 32 of
32
with 100 triples per page.
- Q5058353 subject Q7163797.
- Q5058353 subject Q8645726.
- Q5058353 abstract "Death rates due to heart failure continue to rise steadily in the western world despite better strategies designed to salvage damaged or dying myocardium after myocardial infarction. In the United States alone, it is estimated that 5 million people have congestive heart failure presently and 500,000 more are diagnosed each year. The most prominent cause of myocardial infarction (MI) and subsequent myocardial cell death is undiagnosed coronary artery disease resulting in plaque rupture or dislodgement and myocardial cell ischemia. After an MI, myocardial cells that die or are damaged are replaced by collagen and fibroblasts in a healing process that remodels the heart, most typically the left ventricle. This tissue is non-functioning scar tissue and often leads to a permanent decrease in the efficiency of the myocardium.Cellular cardiomyoplasty, or cell-based cardiac repair, is a new potential therapeutic modality in which progenitor cells are used to repair regions of damaged or necrotic myocardium. The ability of transplanted progenitor cells to improve function within the failing heart has been shown in experimental animal models and in some human clinical trials. In November 2011, a large group of collaborators at Minneapolis Heart Institute Foundation at Abbott Northwestern found no significant difference in left ventricular ejection fraction (LVEF) or other markers, between a group of patients treated with cellular cardiomyoplasty and a group of control patients. In this study, all patients were post MI, post percutaneous coronary intervention (PCI) and that infusion of progenitor cells occurred 2–3 weeks after intervention. In a study that is currently underway (February 2012), however, more positive results were being reported: In the SCIPIO trial, patients treated with autologous cardiac stem cells post MI have been reported to be showing statistically significant increases in LVEF and reduction in infarct size over the control group at four months after implant. Positive results at the one-year mark are even more pronounced.Yet the SCIPIO trial "was recently called into question". Harvard University is "now investigating the integrity of some of the data". The Lancet recently published an non-specific ‘Expression of concern’ about the paper.Subsequently another preclinical study also raised doubts on the rational behind using this special kind of cells, as it was found that the special cells only have a minimal ability in generating new cardiomyocytes. Some specialists therefore now raise concerns to continue.".
- Q5058353 wikiPageWikiLink Q111140.
- Q5058353 wikiPageWikiLink Q12152.
- Q5058353 wikiPageWikiLink Q1660197.
- Q5058353 wikiPageWikiLink Q181754.
- Q5058353 wikiPageWikiLink Q188151.
- Q5058353 wikiPageWikiLink Q1896218.
- Q5058353 wikiPageWikiLink Q200741.
- Q5058353 wikiPageWikiLink Q2008344.
- Q5058353 wikiPageWikiLink Q210861.
- Q5058353 wikiPageWikiLink Q212354.
- Q5058353 wikiPageWikiLink Q21608541.
- Q5058353 wikiPageWikiLink Q2642600.
- Q5058353 wikiPageWikiLink Q26868.
- Q5058353 wikiPageWikiLink Q379071.
- Q5058353 wikiPageWikiLink Q407384.
- Q5058353 wikiPageWikiLink Q408378.
- Q5058353 wikiPageWikiLink Q428914.
- Q5058353 wikiPageWikiLink Q463418.
- Q5058353 wikiPageWikiLink Q631521.
- Q5058353 wikiPageWikiLink Q641303.
- Q5058353 wikiPageWikiLink Q7163797.
- Q5058353 wikiPageWikiLink Q725508.
- Q5058353 wikiPageWikiLink Q7430.
- Q5058353 wikiPageWikiLink Q84133.
- Q5058353 wikiPageWikiLink Q844935.
- Q5058353 wikiPageWikiLink Q8645726.
- Q5058353 wikiPageWikiLink Q904082.
- Q5058353 comment "Death rates due to heart failure continue to rise steadily in the western world despite better strategies designed to salvage damaged or dying myocardium after myocardial infarction. In the United States alone, it is estimated that 5 million people have congestive heart failure presently and 500,000 more are diagnosed each year.".
- Q5058353 label "Cellular cardiomyoplasty".